These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 31822974)

  • 1. Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer.
    Borggreve AS; Heethuis SE; Boekhoff MR; Goense L; van Rossum PSN; Brosens LAA; van Lier ALHMW; van Hillegersberg R; Lagendijk JJW; Mook S; Ruurda JP; Meijer GJ
    Eur Radiol; 2020 Apr; 30(4):1896-1907. PubMed ID: 31822974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion-weighted MRI and
    Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
    Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using
    Borggreve AS; Goense L; van Rossum PSN; Heethuis SE; van Hillegersberg R; Lagendijk JJW; Lam MGEH; van Lier ALHMW; Mook S; Ruurda JP; van Vulpen M; Voncken FEM; Aleman BMP; Bartels-Rutten A; Ma J; Fang P; Musall BC; Lin SH; Meijer GJ
    Int J Radiat Oncol Biol Phys; 2020 Apr; 106(5):998-1009. PubMed ID: 31987972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer.
    van Rossum PS; van Lier AL; van Vulpen M; Reerink O; Lagendijk JJ; Lin SH; van Hillegersberg R; Ruurda JP; Meijer GJ; Lips IM
    Radiother Oncol; 2015 May; 115(2):163-70. PubMed ID: 26002307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor volume regression during neoadjuvant chemoradiotherapy for esophageal cancer: a prospective study with weekly MRI.
    Defize IL; Boekhoff MR; Borggreve AS; van Lier ALHMW; Takahashi N; Haj Mohammad N; Ruurda JP; van Hillegersberg R; Mook S; Meijer GJ
    Acta Oncol; 2020 Jul; 59(7):753-759. PubMed ID: 32400242
    [No Abstract]   [Full Text] [Related]  

  • 6. DW-MRI and DCE-MRI are of complementary value in predicting pathologic response to neoadjuvant chemoradiotherapy for esophageal cancer.
    Heethuis SE; Goense L; van Rossum PSN; Borggreve AS; Mook S; Voncken FEM; Bartels-Rutten A; Aleman BMP; van Hillegersberg R; Ruurda JP; Meijer GJ; Lagendijk JJW; van Lier ALHMW
    Acta Oncol; 2018 Sep; 57(9):1201-1208. PubMed ID: 29781342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.
    Borggreve AS; Mook S; Verheij M; Mul VEM; Bergman JJ; Bartels-Rutten A; Ter Beek LC; Beets-Tan RGH; Bennink RJ; van Berge Henegouwen MI; Brosens LAA; Defize IL; van Dieren JM; Dijkstra H; van Hillegersberg R; Hulshof MC; van Laarhoven HWM; Lam MGEH; van Lier ALHMW; Muijs CT; Nagengast WB; Nederveen AJ; Noordzij W; Plukker JTM; van Rossum PSN; Ruurda JP; van Sandick JW; Weusten BLAM; Voncken FEM; Yakar D; Meijer GJ;
    BMC Cancer; 2018 Oct; 18(1):1006. PubMed ID: 30342494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of pathologic responders to neoadjuvant chemoradiotherapy by diffusion-weighted magnetic resonance imaging in locally advanced esophageal squamous cell carcinoma: a prospective study.
    Li QW; Qiu B; Wang B; Wang DL; Yin SH; Yang H; Liu JL; Fu JH; Liu MZ; Xie CM; Liu H
    Dis Esophagus; 2018 Feb; 31(2):. PubMed ID: 29036528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
    Anderegg MCJ; van der Sluis PC; Ruurda JP; Gisbertz SS; Hulshof MCCM; van Vulpen M; Mohammed NH; van Laarhoven HWM; Wiezer MJ; Los M; van Berge Henegouwen MI; van Hillegersberg R
    Ann Surg Oncol; 2017 Aug; 24(8):2282-2290. PubMed ID: 28424936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
    Goense L; Visser E; Haj Mohammad N; Mook S; Verhoeven RHA; Meijer GJ; van Rossum PSN; Ruurda JP; van Hillegersberg R
    Eur J Surg Oncol; 2018 May; 44(5):620-625. PubMed ID: 29478739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
    Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
    Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer.
    Vollenbrock SE; Voncken FEM; van Dieren JM; Lambregts DMJ; Maas M; Meijer GJ; Goense L; Mook S; Hartemink KJ; Snaebjornsson P; Ter Beek LC; Verheij M; Aleman BMP; Beets-Tan RGH; Bartels-Rutten A
    Br J Surg; 2019 Apr; 106(5):596-605. PubMed ID: 30802305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusion-weighted magnetic resonance imaging in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    De Felice F; Magnante AL; Musio D; Ciolina M; De Cecco CN; Rengo M; Laghi A; Tombolini V
    Eur J Surg Oncol; 2017 Jul; 43(7):1324-1329. PubMed ID: 28363512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diffusion-weighted magnetic resonance imaging (DWI) predicts the early response of esophageal squamous cell carcinoma to concurrent chemoradiotherapy.
    Wang L; Liu L; Han C; Liu S; Tian H; Li Z; Ren X; Shi G; Wang Q; Wang G
    Radiother Oncol; 2016 Nov; 121(2):246-251. PubMed ID: 27838148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early regression index (ERI) on MR images as response predictor in esophageal cancer treated with neoadjuvant chemo-radiotherapy: Interim analysis of the prospective ESCAPE trial.
    Fiorino C; Palumbo D; Mori M; Palazzo G; Pellegrini AE; Albarello L; Belardo A; Canevari C; Cossu A; Damascelli A; Elmore U; Mazza E; Pavarini M; Passoni P; Puccetti F; Slim N; Steidler S; Del Vecchio A; Di Muzio NG; Chiti A; Rosati R; De Cobelli F
    Radiother Oncol; 2024 May; 194():110160. PubMed ID: 38369025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
    Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
    J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
    Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
    Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of variations in intra-fraction motion of esophageal tumors over the course of neoadjuvant chemoradiotherapy based on cine-MRI.
    Heethuis SE; Borggreve AS; Goense L; van Rossum PSN; Mook S; van Hillegersberg R; Ruurda JP; Meijer GJ; Lagendijk JJW; van Lier ALHMW
    Phys Med Biol; 2018 Jul; 63(14):145019. PubMed ID: 29952315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Predictive value of combination of MRI tumor regression grade and apparent diffusion coefficient for pathological complete remission after neoadjuvant treatment of locally advanced rectal cancer].
    Xu N; Huang FC; Li WL; Luan X; Jiang YM; He B
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Apr; 24(4):359-365. PubMed ID: 33878826
    [No Abstract]   [Full Text] [Related]  

  • 20. Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma.
    Kathiravetpillai N; Koëter M; van der Sangen MJ; Creemers GJ; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
    Eur J Surg Oncol; 2016 Aug; 42(8):1183-90. PubMed ID: 27134188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.